HC Wainwright & Co. Maintains Buy on Lineage Cell Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.
HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.